Ryan Bjordahl

This inventor holds 19 USPTO granted patents and 17 published patent applications and 4 EPO patents, primarily in Immunotherapy Techniques. Top assignee: Fate Therapeutics, Inc.. Active years: 2019-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Ryan Bjordahl. Retrieved from https://idiyas.com/inventor/ryan-bjordahl

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 19 (Patent Applications = 17)

% Patents Active = 100.0

EPO Patents = 4 (Patent Applications = 15)

Average Co-Inventor Count = 4.0

ph-index = 6

Forward Citations = 105(Granted Patents)

Company Filing History:

19 out of 51

Fate Therapeutics, Inc.

patents

Years Active: 2019-2026

Loading Chart...

Areas of Expertise:

Genomic Engineering

Pluripotent Cells

Immunotherapies

iPSC Derived Cells

Immune Modulation

Adoptive Immunotherapy

Hematopoietic Cell Differentiation

Effector Cells

Cell Types

Compositions

Methods

19 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12642852 - Genomic engineering of pluripotent cells (2026-06-02),

2. 12435123 - Immunotherapies using enhanced iPSC derived effector cells (2025-10-07),

3. 12419870 - Compositions and methods for immune cell modulation in adoptive immunotherapies (2025-09-23),

4. 12410403 - Methods and compositions for inducing hematopoietic cell differentiation (2025-09-09),

5. 12398373 - Enhanced immune effector cells and use thereof (2025-08-26),

6. 12281329 - Compositions and methods for immune cell modulation in adoptive immunotherapies (2025-04-21),

7. 12275955 - Combining iPSC derived effector cell types for immunotherapy use (2025-04-14),

8. 12173274 - Enhanced immune effector cells and use thereof (2024-12-24),

9. 11413309 - Compositions and methods for immune cell modulation in adoptive immunotherapies (2022-08-16),

10. 11365394 - Enhanced immune effector cells and use thereof (2022-06-21),

11. 11352607 - Genomic engineering of pluripotent cells (2022-06-07),

12. 11162076 - Methods and compositions for inducing hematopoietic cell differentiation (2021-11-02),

13. 11162075 - Methods and compositions for inducing hematopoietic cell differentiation (2021-11-02),

14. 11096964 - Compositions and methods for immune cell modulation in adoptive immunotherapies (2021-08-24),

15. 11072781 - Genomic engineering of pluripotent cells (2021-07-27),

Title: Innovations of Ryan Bjordahl in Immunotherapy

Introduction

Ryan Bjordahl, based in San Diego, California, is an accomplished inventor recognized for his significant contributions to the field of immunotherapy. With a portfolio that includes 19 patents, Bjordahl has made considerable strides in enhancing various therapeutic approaches, particularly through the application of induced pluripotent stem cells (iPSCs).

Latest Patents

Bjordahl's recent patents showcase groundbreaking methods and compositions for advancing cancer therapies. One notable patent focuses on "Immunotherapies using enhanced iPSC derived effector cells," which outlines techniques for obtaining enhanced derivative effector cells from genomically engineered iPSCs. These cells possess stable genomic modifications that yield improved therapeutic effects. Another key patent emphasizes "Compositions and methods for immune cell modulation in adoptive immunotherapies," identifying compounds that increase the efficacy of T, NK, and NKT cells in cell therapies.

Career Highlights

Currently, Ryan Bjordahl is associated with Fate Therapeutics, Inc., a leading biotech company dedicated to developing transformative cell therapies. His role at the company allows him to drive innovations that are set to improve patient outcomes significantly. Throughout his career, Bjordahl has been at the forefront of research that merges cutting-edge science with practical therapeutic applications.

Collaborations

At Fate Therapeutics, Bjordahl collaborates with esteemed colleagues including Bahram Valamehr and Tom Tong Lee. Together, they work on pioneering projects that harness the power of cellular engineering to develop novel immunotherapeutic approaches.

Conclusion

Ryan Bjordahl stands out as an influential inventor in the field of immunotherapy, with a robust portfolio of patents that pave the way for new treatments. His innovative work, combined with collaborations at Fate Therapeutics, promises to make a significant impact on the future of medical therapies aimed at combating diseases like cancer.

Profile summary based on public USPTO records.